Denovo Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.60 M
as on 02-12-2024
- Paid Up Capital ₹ 0.60 M
as on 02-12-2024
- Company Age 18 Year, 7 Days
- Last Filing with ROC 31 Mar 2021
- Open Charges ₹ 3.50 M
as on 02-12-2024
About Denovo Pharmaceuticals
The Company is engaged in the Trading Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2021. It's a company limited by shares with an authorized capital of Rs 0.60 M and a paid-up capital of Rs 0.60 M.
The company currently has active open charges totaling ₹3.50 M.
Deepak Garg, Sanjeev Garg, and Manish Garg serve as directors at the Company.
- CIN/LLPIN
U24232PB2006PTC030764
- Company No.
030764
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
19 Dec 2006
- Date of AGM
30 Nov 2021
- Date of Balance Sheet
31 Mar 2021
- Listing Status
Unlisted
- ROC Code
Roc Chandigarh
Industry
Company Details
- Location
Muktsar, Punjab, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Denovo Pharmaceuticals Private Limited offer?
Denovo Pharmaceuticals Private Limited offers a wide range of products and services, including Mineral Supplement, Ferrous Ascorbate Tablet, Multivitamin Tablets & Capsules, Antioxidant Capsule, Softgel Capsules, Lubiprostone Soft Gelatin Capsule, Pharma Franchise, PCD Pharma Franchise, Nutraceuticals & Dietary Supplements, Dietary Supplements.
Who are the key members and board of directors at Denovo Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Deepak Garg  | Director | 31-Mar-2015 | Current |
| Sanjeev Garg | Director | 01-Jul-2011 | Current |
| Manish Garg | Director | 20-Jul-2017 | Current |
Financial Performance of Denovo Pharmaceuticals.
Denovo Pharmaceuticals Private Limited, for the financial year ended 2017, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Denovo Pharmaceuticals?
In 2017, Denovo Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
State Bank Of Patiala Creation Date: 28 Sep 2012 | ₹3.50 M | Open |
How Many Employees Work at Denovo Pharmaceuticals?
Unlock and access historical data on people associated with Denovo Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Denovo Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Denovo Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
